Pretty much what I was looking for. Happy with this quarterly. The commercialization has begun. Record revenues per quarter should be the norm from this quarterly onwards. Balance sheet looks good for at least 4-5 quarters, given the July $1.93m payment, the $5.5m R+D rebate and the October Claws annual distribution. FWIW, I would be expecting that this years payment is substantially larger than last years $2.6m. The great unknown remains the payment size for the projects and whether or not BLG has won either of the two they applied for. Be curious to know how many applications they made this year in the "call for topics". The winners of these should be known in December 24 with the projects allocated in June 25. ( and by June I mean August, given this years delay!! ) Future raises will all depend on whether the 4.6c and 6c options are in the money when they expire in Feb 25 and Feb 27 respectively. A project win or two, would have the SP much higher than currently and no need for future cap raises/ dilution.
Holding tight and hopeful CLAWS project are announced imminently.
BLG Price at posting:
3.4¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)